Second primary cancer after irradiation of laryngeal cancer.

Ann Otol Rhinol Laryngol

Published: February 1976

Thirty (5.6%) of 535 patients followed 5-25 years after treatment of cordal carcinoma (T1A,B) developed a second primary laryngeal carcinoma. When analyzed by treatment modality, 3.9% of operated cases and 9% of irradiated cases formed new laryngeal or laryngopharyngeal malignancies. An explanation by radiation-induced carcinogenesis for this statistically significant difference between the two groups is discussed. It is also suggested that supervoltage radiation directed to the laryngeal mucosa may produce the diminished latent period observed between the appearance of the second primary carcinoma.

Download full-text PDF

Source
http://dx.doi.org/10.1177/000348947508400607DOI Listing

Publication Analysis

Top Keywords

second primary
12
primary cancer
4
cancer irradiation
4
laryngeal
4
irradiation laryngeal
4
laryngeal cancer
4
cancer thirty
4
thirty 56%
4
56% 535
4
535 patients
4

Similar Publications

Purpose The present study aimed to clarify the distribution pattern of carcinoma associated fibroblasts (CAFs) across pancreatic ductal adenocarcinoma (PDAC) and its prognostic prediction value. Methods Data of two cohorts were retrospectively collected from consecutive patients who underwent primary pancreatic resection from January 2015 to December 2017. We used tumor specimens to screen out the most suitable markers for the spatial distribution analysis for CAFs subpopulations.

View Article and Find Full Text PDF

Objectives: The aims of the study were to identify the characteristics of medication-related malpractice claims occurring in the ambulatory setting across 2 time periods.

Methods: A retrospective, descriptive study was used. Ambulatory medication-related closed malpractice events from loss years of 2011-2021 were analyzed.

View Article and Find Full Text PDF

Objective: This study aims to analyze adverse drug events (ADE) related to romosozumab from the second quarter of 2019 to the third quarter of 2023 from FAERS database.

Methods: The ADE data related to romosozumab from 2019 Q2 to 2023 Q3 were collected. After data normalization, four signal strength quantification algorithms were used: ROR (Reporting Odds Ratios), PRR (Proportional Reporting Ratios), BCPNN (Bayesian Confidence Propagation Neural Network), and EBGM (Empirical Bayesian Geometric Mean).

View Article and Find Full Text PDF

Association between hormone therapy and glioma risk in US women: a cancer screening trial.

Menopause

January 2025

From the Department of Neurosurgery, Chongqing General Hospital, Chongqing University, Chongqing, China.

Objective: Gliomas are the most common primary brain tumors in adults, and the role of hormone therapy (HT) in their development remains controversial. This study with a cohort design aimed to investigate the association between HT use and glioma risk using the data from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.

Methods: We analyzed data from 75,335 women, aged 50-78, who were enrolled between 1993 and 2001.

View Article and Find Full Text PDF

Early Versus Delayed Antihypertensive Treatment After Acute Ischemic Stroke by Hypertension History.

Stroke

January 2025

Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, China. (X.X., X.L., Y.P., Yufei Wei, Y.J., M.W., J.J., X.M., Yilong Wang, Yongjun Wang, L.L.).

Background: We performed a prespecified subgroup analysis of the CATIS-2 trial (China Antihypertensive Trial in Acute Ischemic Stroke II) to compare the effect of early versus delayed antihypertensive treatment on death and disability in patients with and without medical history of hypertension.

Methods: CATIS-2 is a multicenter randomized clinical trial conducted in 106 hospitals in China. The trial randomized 4810 patients with acute ischemic stroke within 24 to 48 hours of symptom onset and elevated systolic blood pressure between 140 and <220 mm Hg to receive antihypertensive treatment immediately after randomization or to discontinue antihypertensive medications for 7 days and then receive treatment on day 8.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!